Pascolizumab

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NamePascolizumab
Drug Alias NameAnti-IL-4 monoclonal antibody (Protein Design Labs)Anti-interleukin-4 monoclonal antibody (GlaxoSmithKline)Anti-interleukin-4 monoclonal antibody (Protein Design Labs)Anti-IL-4 monoclonal antibody (GlaxoSmithKline)SB-240683
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-4 inhibitors
TargetsInterleukin-4
Therapy Area/IndicationsAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline PlcPdl Biopharma Inc
Active IndicationsN/A
Inactive IndicationsAsthma

Other Information

ATC CodeN/A
Related LinksN/A